Insight Molecular Diagnostics Inc. (IMDX)
Market Closed
17 Jul, 20:00
NASDAQ (CM) 
$
4. 74
+0.03
+0.6369%
$
- Market Cap
- P/E Ratio
- Div Yield
39,100 Volume
- Eps
$ 4.71
Previous Close Want to track IMDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IMDX closed today higher at $4.74, an increase of 0.6369% from yesterday's close, completing a monthly decrease of -23.0519% or -$1.42. Over the past 12 months, IMDX stock lost -36.631%.
IMDX is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports.
Insight Molecular Diagnostics Inc. has completed 1 stock splits, with the recent split occurring on Jul 25, 2023.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
IMDX Chart
Insight Molecular Diagnostics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 12,250 | $40,180 | $56,351.22 | $16,171.22 | 40.25% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $3.28 | $4.75 | $1.47 | 44.82% |
| CCW Cassaday & Co. Wealth Management LLC Cassaday & Co. Wealth Management LLC | 10 | $33 | $47.5 | $14.5 | 43.94% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1 | $3.28 | $4.74 | $1.46 | 44.51% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 1 | $3.28 | $4.75 | $1.47 | 44.82% |
Insight Molecular Diagnostics Inc. (IMDX) FAQ
What is the stock price today?
The current price is $4.74.
On which exchange is it traded?
Insight Molecular Diagnostics Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is IMDX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Insight Molecular Diagnostics Inc. ever had a stock split?
Insight Molecular Diagnostics Inc. had 1 splits and the recent split was on Jul 25, 2023.
Insight Molecular Diagnostics Inc. Profile
| - Industry | - Sector | Mr. Joshua Riggs CEO | NASDAQ (CM) Exchange | 68235C206 CUSIP |
| United States Country | 55 Employees | - Last Dividend | 25 Jul 2023 Last Split | - IPO Date |
Overview
Insight Molecular Diagnostics Inc. is a pioneering precision diagnostics company dedicated to the development and commercialization of sophisticated molecular diagnostic tests tailored for both clinical and research applications. The company, founded in 2009 and headquartered in Nashville, emphasizes a core focus on transplant medicine and oncology. By addressing critical unmet needs in patient care, Insight Molecular Diagnostics plays a transformative role in enhancing patient outcomes through personalized and real-time interventions. Their innovative approach not only aids in patient monitoring but also supports advancements in in-vitro diagnostics and biomarker discovery through collaboration with leading industry professionals such as Bio-Rad Laboratories.
Products and Services
- VitaGraft Kidney Test: A blood-based diagnostic assay designed to monitor kidney transplant rejection by detecting donor-derived cell-free DNA. This innovative test enables healthcare providers to assess the health of transplanted organs in a timely manner, potentially leading to better patient outcomes.
- VitaGraft Liver Test: Similar to the VitaGraft Kidney Test, this assay focuses on liver transplants. It utilizes cutting-edge blood-based detection methods to monitor for potential organ rejection, ensuring that patients receive the necessary interventions promptly.
- GraftAssure Suite: Leveraging droplet digital PCR technology, this suite of tests offers highly sensitive monitoring capabilities for transplant patients. It aids clinicians in determining the likelihood of transplant rejection, fostering proactive measures in patient management.
- DetermaCNI: Targeting the oncology sector, this blood-based assay detects early progression of cancer after a single cycle of treatment. DetermaCNI empowers oncologists with critical information that can influence treatment decisions and improve patient prognosis.
- DetermaIO: This innovative test predicts a patient’s response to immunotherapies by evaluating factors within the tumor microenvironment. DetermaIO is poised to inform treatment plans, enabling clinicians to tailor their approaches based on predicted outcomes.
- Biomarker Discovery: Insight Molecular Diagnostics actively engages in the discovery of biomarkers, facilitating the identification of novel diagnostic targets that can further enhance precision medicine applications in various health conditions.
- Assay Development: The company specializes in the development of custom assays tailored to the needs of research and clinical applications, thereby enhancing diagnostic capabilities in the healthcare field.
- Clinical Trial Support: By collaborating with pharmaceutical partners, Insight Molecular Diagnostics supports clinical trials aimed at validating the efficacy of new diagnostics. This service is essential for advancing innovative treatment options across different therapeutic landscapes.
Contact Information
Address: 2 International Plaza Dr.
Phone: 949 409 7600
Website: https://www.imdxinc.com
